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2Abstract
Interleukin-10 (IL-10) signaling has been suggested to play a role in systemic sclerosis (SSc). 
IL10RB codes for IL-10 receptor 2 (IL-10R2), a component shared in receptor complexes for 
IL-10, IL-22, IL-26 and interferon (IFN)-. In this study, we examined association of IL10RB
polymorphism with susceptibility to SSc. Genotype A/A at rs2834167 (47K/K) was 
significantly increased in diffuse cutaneous SSc (dcSSc) (41.3% in dcSSc, 20.9% in controls, 
P=0.0018, odds ratio = 2.67). A SNP in the 5’ flanking region of IL10RB, rs999788, also 
showed association with dcSSc; however, this association was shown to be secondarily 
caused by linkage disequilibrium with rs2834167. Significant association was not observed 
in limited cutaneous SSc (lcSSc). Presence of anti-topoisomerase I antibody was also 
associated with rs2834167A/A genotype (P=0.0019). Serum IL-10 level was significantly
associated with the number of rs2834167A allele (P=0.007). These findings suggested that 
signaling through IL-10R2 may play a causative role in dcSSc. 
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3Introduction
Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of skin, 
muscles and other organs as well as vascular damage [1]. SSc is subdivided into limited
cutaneous (lcSSc) and diffuse cutaneous SSc (dcSSc) according to the extent of skin 
sclerosis. Patients with dcSSc have significant and early incidence of internal organ
involvement such as lung fibrosis and scleroderma renal crisis. In contrast, lcSSc patients 
have a low prevalence of internal organ involvement, except for pulmonary hypertension [2]. 
Specific autoantibodies are associated with distinct types of SSc; anti-topoisomerase I 
antibody is frequently detected in dcSSc, while anti-centromere antibody is usually observed 
in lcSSc. 
The pathogenesis of SSc is a complex combination of genetic and environmental factors [3]. 
Several genetic factors such as HLA [4,5], connective-tissue growth factor [6], CD19 [7], 
interleukin-10 (IL10) [8] and CD22 [9] have been associated with SSc.
IL-10 is secreted by monocytes and lymphocytes, and suppresses production of 
pro-inflammatory cytokines and activation of T helper 1 (Th1) cells [10]. In addition, IL-10 
induces proliferation and differentiation of activated B cells, and stimulates antibody 
production [11]. IL-10 also promotes proliferation and cytotoxic activity of CD8+ T cells [12]. 
Several lines of evidence suggested a role of IL-10 in SSc. Serum level of IL-10 was 
elevated in the patients with dcSSc [13], and was positively correlated with skin and 
pulmonary fibrosis [8]. 
Genetic association of IL10 polymorphism with SSc was also reported. Crilly et al. 
suggested that a haplotype with lower IL-10 production may be associated with dcSSc [14], 
while other groups reported that a haplotype with high IL-10 production was associated with 
susceptibility and severity of dcSSc [15,16]. Thus, the role of IL10 polymorphisms in SSc 
remains controversial.
IL-10 receptor complex is composed of IL-10 receptor 1 (IL-10R1) and IL-10R2. IL-10 first 
binds to IL-10R1, and induces a conformational change that enables IL-10R2 to interact with 
IL-10/IL-10R1 complex. This ligand-mediated assembly induces activation of STAT3, 
4followed by induction of STAT3-responsive genes [17]. IL-10R2 is also a component of 
IL-22R, IL-26R and interferon (IFN)-R (IL-28R).
IL-10R2 is encoded by IL10RB gene. IL10RB is located in a class II cytokine receptor gene 
cluster together with IFN receptor 1 (IFNAR1), 2 (IFNAR2) and IFN receptor 2 (IFNGR2) 
on chromosome 21q22. Associations between IL10RB polymorphism and several diseases 
have been reported. Frodsham et al. identified the class II cytokine cluster region as a major 
susceptibility locus for hepatitis B virus (HBV) persistence, and demonstrated that two 
nonsynonymous single nucleotide polymorphisms (SNPs), IFNAR2 F8S and IL10RB E47K, 
were associated with a risk of HBV persistence [18]. IL10RB E47K has also been reported to 
be associated with acute graft-versus-host disease (GvHD) [19]. These observations 
suggested that IL10RB E47K is bears functional significance.
These observations led us to consider IL10RB as a potential candidate susceptibility gene 
for SSc. In the present study, we examined association of IL10RB E47K and three other 
potentially functional SNPs within the same linkage disequilibrium (LD) block with SSc. 
5Materials and Methods 
Patients and controls
Forty-six patients with dcSSc (10 males and 36 females, average age 47.5±16.1 years), 78 
patients with lcSSc (4 males and 74 females, average age 54.8±10.8 years), and healthy 
controls (229 males and 169 females, 28.6±7.3 years) were studied. SSc was classified 
according to the American College of Rheumatology criteria [20]. Patients and healthy 
controls were recruited at Kanazawa University, The University of Tokyo and associated 
laboratories. All patients and healthy controls were unrelated Japanese, living in the central 
part of Japan. This study was reviewed and approved by the Research Ethics Committees of 
University of Tsukuba, Kanazawa University and the University of Tokyo.
Genotyping
IL10RB rs2834167 was genotyped using a bead-array system based on xMAP technology 
(Luminex, Luminex Corp, Austin, TX). The sequences of the primers were as follows: 
5’-CACGTGGCCTTTGAAGACATGG-3’ and 5’- GCCACGAGAATTTCCCAGACAG-3’. 
These primers were labeled with biotinyl-group at 5’-terminus. The PCR products were 
subjected to hybridization with Luminex-beads and labeled with streptavidin conjugated 
phycoerythrin. Each bead was conjugated with the allele specific oligonucleotide probe. The 
sequences of the probes were as follows: 5’- CTTTTGCCAAAGGGAACC-3’ for A allele and 
5’- CTTTTGCCGAAGGGAACC-3’ for G allele. The validity of this method was confirmed by 
direct sequencing.
IL10RB rs999788, IFNAR2 rs4986956 and rs7279064 were genotyped by direct sequencing. 
PCR primers were designed by using Primer3 software. The sequences of the primers for
rs4986956 and rs7279064 were 5’-TGAGACCAGGCTCACTTGAA-3’ and 
5’-GACTTCCTGCCAGTGCTCTC-3’, and those for rs999788 were 
5’-TGGGTTGATCTTTTGCGATA-3’ and 5’-AAGCAGAGGGAAGTGAATGC-3’. PCR 
products were subjected to sequencing reaction using a BigDye Terminator v3.1 Cycle 
Sequencing kit, and sequenced by ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, 
6Foster City, CA).
ELISA 
Serum levels of IL-10 in the patients with dcSSc were measured by ELISA using Human 
IL-10 ELISA Set (BD Biosciences Pharmingen, San Diego, CA) following the manufacturer’s 
instructions. 
Statistical analysis
Association analyses were conducted by 2 test for 2×2 and 2×3 contingency tables. When 
one or more of the variables in the contingency tables was 5 or less, Fisher’s exact test was 
employed. D’ values were calculated using Haploview software 
(http://www.broad.mit.edu/mpg/haploview/download.php). 
Association of rs2834167 genotype and serum IL-10 levels in 44 patients with dcSSc was 
analyzed by simple regression analysis. Genotypes G/G, G/A and A/A were encoded as 0, 1 
and 2, respectively.
7Results
Association of IL10RB E47K with dcSSc
We initially focused on IL10RB rs2834167 coding for a nonsynonymous substitution E47K, 
because this SNP was associated with other conditions [18,19] and considered likely to be 
functional. As shown in Table 1, rs2834167 A/A genotype (47K/K) was significantly 
increased in SSc under the recessive model (P=0.038, odds ratio [OR] =1.61, 95% 
confidence interval [CI]: 1.02-2.54). The genotype frequency in our controls was compatible 
with Hardy-Weinberg equilibrium, and was quite similar to that in the 934 Japanese 
volunteers (G/G 0.30, G/A 0.49, A/A 0.21) in the JSNP database 
(http://snp.ims.u-tokyo.ac.jp/index.html).
This association was attributable to the dcSSc subgroup, since the difference between 
dcSSc and controls was highly significant (P=0.0018, OR = 2.67, 95% CI : 1.42-5.04), while
significant difference was not observed between lcSSc and controls. Similarly, when the 
patients were classified according to the presence of anti-topoisomerase I and 
anti-centromere antibodies, significant association of rs2834167 A/A genotype was 
observed only in the anti-topoisomerase I antibody positive group (P=0.0019, OR = 3.00, 
95%CI 1.50-5.99). 
We next examined whether this SNP is causally associated with dcSSc, or only represents 
LD with other causal alleles. According to the HapMap database 
(http://www.hapmap.org/index.html.en), the LD block encompassing rs2834167 extends 
from IFNAR2 to exon 2 of IL10RB. Within this LD block, three potentially functional SNPs 
other than rs2834167 are present (Fig. 1). A SNP in the 5’ flanking region of IL10RB, 
rs999788, is located at a NF-B binding site, and a transcription factor binding site prediction 
program (MATCH, http://www.gene-regulation.com/index.html) predicted that rs999788 T 
allele, but not C allele, forms the binding site of NF-B. Two nonsynonymous SNPs of 
IFNAR2, rs4986956 (F8S) and rs7279064 (V10F), are also included in the LD block. Both 
the IL10RB and IFNAR2 genes have been shown to be associated with HBV persistence 
[18].
8We therefore examined whether these SNPs are associated with SSc. As shown in Table 1, 
IL10RB rs999788 C/C genotype was significantly increased in SSc (P = 0.028, OR = 1.65, 
95%CI 1.05-2.59). This association was again mainly attributable to dcSSc. On the other 
hand, significant association was not observed between IFNAR2 SNPs and SSc. All control 
genotypes were compatible with Hardy-Weinberg equilibrium.
Primary contribution of rs2834167
The two IL10RB SNPs associated with SSc, rs2834167 and rs999788, were found to be in 
strong LD (Fig. 1). To distinguish the contributions, two-locus analysis was performed (Table 
2). Subjects were classified into four groups (a-d) with respect to the carriage of the risk 
genotype at rs2834167 (A/A) and rs999788 (C/C), and each risk of group a-c was compared 
with that of group d. While the OR was significantly elevated in the group b carrying only the 
risk genotype at rs2834167, no patient belonged to the group c carrying the risk genotype 
only at rs999788, suggesting that rs2834167 plays a primary role of the two SNPs.
This issue was also addressed by haplotype analysis (Table 3). If rs999788 also contributes 
to the genetic risk to SSc, then the haplotype containing risk alleles of both SNPs should 
reveal strong association. Seven haplotypes were inferred, but permutation test revealed no 
significant difference in the haplotype frequency between dcSSc and controls. 
These results suggested that rs2834167 encoding E47K, rather than the 5’ flanking region 
polymorphism rs999788, is primarily associated with dcSSc.
Association of IL10RB rs2834167 polymorphism and serum levels of IL-10
IL-10 has been shown to induce IL-10 production via STAT3, and also to suppress 
LPS-induced production of IL-10 by a STAT3-independent pathway [21]. To address the 
functional significance of IL10RB rs2834167 polymorphism, we compared serum IL-10 
levels in 44 patients with dcSSc of each genotype (G/G 14, G/A 12, A/A 18). As shown in Fig.
2, serum IL-10 levels were significantly correlated with the number of rs2834167A allele 
(P=0.007).
9Discussion
In the present study, we showed that rs2834167 coding for IL10RB E47K was associated 
with susceptibility to dcSSc. IL10RB gene has never been studied for the association of SSc. 
Our findings provided new evidence that supports the causal role of IL-10 or related cytokine 
signaling in the pathogenesis of SSc.
IL-10 stimulates B cells and T helper 2 (Th2) cells, which may result in production of 
autoantibodies. In the TSK/+ mouse, a genetic model for human SSc, loss of CD19 
significantly decreased skin fibrosis as well as hypergammaglobulinemia and autoantibody 
production [22]. In addition to the roles on the B cells, IL-10 can promote fibrosis by 
modulating the Th1/Th2 balance. IL-4, IL-6, and IL-13 stimulate the synthesis of collagen by 
human fibroblasts [23], while Th1 cytokines such as IFN- and TNF- suppress collagen 
production by fibroblasts [23]. Anti-IL-4 treatment [24] and IL-4R disruption[25] have been 
shown to ameliorate fibrosis in TSK/+ mice. In a silica-induced lung fibrosis model, 
pulmonary overexpression of IL-10 induced profibrotic Th2 cytokines IL-4 and IL-13, and 
exacerbated lung fibrosis [26]. These observations indicate a crucial role for B cells and Th2 
in skin fibrosis in in vitro and animal studies.
The role of B cells and Th2 cells have also been shown in human SSc [27]. We previously 
reported association of SNPs in CD19 [7] and CD22 [9] with human SSc. Serum IL-10 level
was elevated in dcSSc [13], and was positively correlated with skin and pulmonary fibrosis 
[8]. These results support that excessive IL-10 signaling may lead to fibrosis, and suggest 
that IL10RB 47K allele product leads to excessive IL-10 signaling. 
IL10 gene is located on 1q31-32; therefore, IL10 SNPs cannot be in LD with IL10RB. Thus, 
association of serum IL-10 levels with IL10RB should be explained by a functional 
connection between IL-10R signaling and IL-10 induction. IL-10 has been shown to induce 
IL-10 production via STAT3, and also to suppress LPS-induced production of IL-10 by a 
STAT3-independent pathway in primary human monocyte - derived macrophages [21]. Two 
hypotheses can be envisaged on the mechanisms of elevated serum IL-10 in individuals 
with IL10RB 47K/K genotype.
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The first possibility is that IL-10R2 E47K substitution induces stronger signals in 
STAT3-dependent pathway of IL-10 production. IL-10R2 contributes little to IL-10 binding 
affinity, but acts as an accessory subunit for signaling when IL-10 binds to IL-10R1. The 
principal function of IL-10R2 appears to be a recruitment of a Jak kinase (Tyk2) into the 
signaling pathway, which subsequently leads to STAT3 activation [17]. E47K substitution 
may enhance STAT3 activation and IL-10 production through the influence on the structure 
of the IL-10 receptor complex, since the SNP E47K introduces a nonconservative 
substitution in the extracellular domain.
Another possibility is the reduction of suppression of STAT3-independent IL-10 production
through IL-10R2. Frodsham et al. previously reported that the mRNA expression level of the 
IL10RB 47K allele was lower than that of 47E allele, and that insufficient inhibition mediated 
by IL10RB 47K resulted in higher LPS-induced TNF- release [18]. Similar mechanism is 
likely to play a role in IL-10 production. The lower mRNA expression of IL10RB 47K may be 
due to the strong LD with the promoter SNP rs999788 C that lacks NF-B binding site. 
These possibilities are not mutually exclusive.
IL10RB E47K could also be associated with SSc by mechanisms other than IL-10 signaling. 
IL-10R2 is a shared component of receptors for IL-10, IL-22, IL-26 and IFN- (IL-28, IL-29)
[17]. In relation to the pathogenesis of dcSSc, it is remarkable that IL-20R1 that forms IL-26 
receptor complexes with IL-10R2 is strongly expressed in skin and lung [28]. IL-22R1 is also 
expressed in the lung [29]. Furthermore, IFN- signaling induces similar repertoire of genes 
induced by IFN-/ [30], which have been shown to be upregulated in the peripheral blood 
expression profile of patients with SSc [31]. Thus, IL10RB polymorphism may potentially be 
involved in the pathogenesis of SSc by multiple pathways.
In conclusion, this study suggested that IL10RB E47K contributes to the susceptibility to 
dcSSc. Because the sample size of SSc patients was small, our present observations need 
to be replicated in the future. If confirmed, such findings will provide a link between IL-10 or
related cytokines and fibrosis
11
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Figure legends
Figure 1. Organization of IL10RB and IFNAR2 gene in human chromosome 21 and linkage 
disequilibrium among four SNPs examined in this study,
(upper) Linkage disequilibrium plot constructed based on the Japanese data from the 
International HapMap project (http://www.hapmap.org/index.html.en).
(lower) Pairwise D’ values among the four SNPs calculated using the genotypes of the 
control group in this study. Strong LD was observed between IL10RB rs2834167 and 
rs999788 (D’=0.94) and also between IFNAR2 rs4986956 and rs7279064 (D’=1.0), but LD 
between the SNPs of IL10RB and IFNAR2 was moderate.
Figure 2. Association of IL10RB rs2834167 G>A (E47K) and serum IL-10 level in patients 
with dcSSc.
Serum IL-10 level was correlated with the number of rs2834167A (47K) allele (P = 0.007, 
simple regression analysis).
Figure 1
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Table 1.  Genotype frequencies of four SNPs in IL10RB and IFNAR2 in patients with 
SSc and healthy controls. 
All SSc (n=124) dcSSc (n=46) lcSSc (n=78) controls (n=398)
IL10RB rs2834167G>A (E47K)
G/G 34 (0.27)   14  (0.31)   20  (0.26)  111  (0.28)
G/A 53 (0.43)   13  (0.28)   40  (0.51)  204  (0.51)
A/A 37 (0.30) 1   19  (0.41)2   18 (0.23)   83  (0.21)
IL10RB 5’ flanking region rs999788 T>C
T/T 33 (0.26)   14  (0.30)   19  (0.24)  119  (0.30)
T/C 53 (0.43)   16  (0.35)   37  (0.48)  195  (0.49)
C/C 38 (0.31)3   16  (0.35) 4   22  (0.28)   84  (0.21)
IFNAR2 rs4986956 T>C (F8S)
T/T 97 (0.78)   38  (0.83)   59  (0.76)  297  (0.75)
T/C 26 (0.21)    7  (0.15)   19  (0.24)   96  (0.24)
C/C 1 (0.01)    1  (0.02)    0  (0)    5  (0.01)
IFNAR2 rs7279064 T>G (F10V)
T/T 26 (0.21)   12  (0.26)   14 (0.18)   71  (0.18)
T/G 67 (0.54)   23  (0.50)   44  (0.56)  198  (0.50)
G/G 31 (0.25)   11  (0.24)   20  (0.26)  129  (0.32)
Genotype frequencies are shown in parentheses.
rs2834167 A/A against (G/G + G/A): 1 all SSc versus controls, P = 0.038, OR = 1.61, 95% 
CI 1.02-2.54, 2 dcSSc versus controls: P = 0.0018, OR = 2.67, 95% CI 1.42-5.04.
rs999788 C/C against (T/T + T/C): 3all SSc versus controls, P = 0.028, OR = 1.65, 95% 
CI 1.05-2.59, 2dcSSc vs controls: P = 0.036, OR = 1.99, 95% CI 1.04-3.83.
Other comparisons did not reveal statistical significance.
Table 1
Table 2. Two-locus analysis support a primary role of IL10RB rs2834167A/A (47K/K) genotype
group rs2834167 A/A rs999788 C/C dcSSc (n=46) controls (n=398) OR 95%CI P
a + + 16 (0.35) 78 (0.20) 2.35 1.21-4.57 0.013
b + - 3 (0.07) 5 (0.01) 6.87 1.56-30.30 0.025
c - + 0 (0) 6 (0.02) 0 - -
d - - 27 (0.58) 309 (0.77) referent
Patients with dcSSc and controls were classified into groups a-d according to the presence of the risk genotypes of rs2834167 and 
rs999788. Numbers and proportions (in parentheses) of each group among the patients and controls are shown. Odds ratio, 95% 
confidence interval and P value of each group were calculated against group d.
Table 2
Table 3. Inferred haplotype frequencies in dcSSc and controls.
haplotype SNP1 SNP2 SNP3 SNP4 dcSSc controls Permutated P
1 T G T G 0.260 0.346 0.478
2 T T C A 0.407 0.340 0.788
3 C G T G 0.082 0.098 0.998
4 T T T G 0.092 0.078 0.999
5 T G C A 0.088 0.075 0.694
6 C G C A 0.016 0.028 0.998
7 T G T A 0.044 0.015 0.680
Haplotype frequencies were inferred using Haploview v4.0. 100,000 permutations were performed for association test. 
SNP1: rs4986956 (IFNAR2 F8S), SNP2: rs7279064 (IFNAR2 V10F), SNP3: rs999788, SNP4: rs2834167 (IL10RB E47K)
Table 3
